Peringatan Keamanan

Patients experiencing an overdose of carboplatin may present with pronounced neutropenia and hepatotoxicity.A230478,L32253 Treat patients with symptomatic and supportive measures, which may include delaying their next treatment.A230478

Carboplatin

DB00958

small molecule approved

Deskripsi

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.L32253 Early clinical studies of carboplatin were performed in 1982.A230523 Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.A230463,A230523

Carboplatin was granted FDA approval on 3 March 1989.L32248

Struktur Molekul 2D

Berat 371.254
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The distribution half life of carboplatin is 1.1-2 hours, and the elimination half life was2.6-5.9 hours.[L32253]
Volume Distribusi The apparent volume of distribution after a 30 minute intravenous infusion of 300-500 mg/m<sup>2</sup> was 16 L.[L32253]
Klirens (Clearance) The total body clearance after a 30 minute intravenous infusion of 300-500 mg/m<sup>2</sup> was 4.4 L/h.[L32253]

Absorpsi

The Cmax and AUC of carboplatin increase proportionally with increasing doses.L32253 A 75 mg/m2 dose reaches a Cmax of 9.06 ± 0.74 µg/mL, with an AUC of 27.18 ± 11.28 h\*µg/mL.A230463,L32253 A 450 mg/m2 dose reaches a Cmax of 55.39 ± 18.30 µg/mL, with an AUC of 224.41 ± 69.07 h\*µg/mL.A230463,L32253

Metabolisme

Carboplatin is predominantly eliminated as the unchanged parent compound.A230158,A230473

Rute Eliminasi

Carboplatin is 65% eliminated in the urine within 12 hours, and 71% eliminated within 24 hours.A230463,L32253 An additional 3-5% is eliminated in urine from 24 hours to 96 hours.A230463,L32253 Biliary elimination has not been determined.A230463,L32253 Carboplatin is predominantly eliminated as the unchanged parent compound.A230158,A230473

Interaksi Makanan

1 Data
  • 1. Avoid echinacea. Co-administration may decrease effectiveness of immunosuppressants.

Interaksi Obat

1177 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Carboplatin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carboplatin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carboplatin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carboplatin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Carboplatin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carboplatin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carboplatin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carboplatin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Carboplatin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Carboplatin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Carboplatin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Carboplatin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Carboplatin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Carboplatin.
Cladribine Carboplatin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Carboplatin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Carboplatin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Carboplatin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Carboplatin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Carboplatin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Carboplatin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Carboplatin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Carboplatin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Carboplatin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Carboplatin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Carboplatin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Carboplatin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Carboplatin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Carboplatin.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Carboplatin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Carboplatin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Carboplatin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Carboplatin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Carboplatin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Carboplatin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Carboplatin.
Oxaliplatin The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Carboplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Carboplatin.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Carboplatin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Carboplatin.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Carboplatin.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Carboplatin.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Carboplatin.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Carboplatin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Carboplatin.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Carboplatin.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Carboplatin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Carboplatin.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Carboplatin.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Carboplatin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carboplatin.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Carboplatin.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Carboplatin.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Carboplatin.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carboplatin.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carboplatin.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Carboplatin.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Carboplatin.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Carboplatin.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Carboplatin.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carboplatin.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Carboplatin is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Carboplatin is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Carboplatin is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Carboplatin is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Carboplatin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Carboplatin is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Carboplatin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Carboplatin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Carboplatin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Carboplatin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Carboplatin is combined with Flucytosine.
Capecitabine Capecitabine may increase the nephrotoxic activities of Carboplatin.
Trilostane The risk or severity of adverse effects can be increased when Carboplatin is combined with Trilostane.
Procarbazine The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide.

Target Protein

DNA

Referensi & Sumber

Synthesis reference: Jingzun Wang, Huisheng Qu, Lei Wang, Ting Wang, "Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions." U.S. Patent US07259270, issued August 21, 2007.
Artikel (PubMed)
  • PMID: 3512077
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972-9.
  • PMID: 21135941
    Sooriyaarachchi M, Narendran A, Gailer J: Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro. Metallomics. 2011 Jan;3(1):49-55. doi: 10.1039/c0mt00058b. Epub 2010 Dec 6.
  • PMID: 3283185
    Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1988 Mar;28(3):208-15. doi: 10.1002/j.1552-4604.1988.tb03134.x.
  • PMID: 7527485
    Povirk LF, Shuker DE: DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 1994 Dec;318(3):205-26. doi: 10.1016/0165-1110(94)90015-9.
  • PMID: 3036389
    Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL, Morstyn G: Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma. Cancer Chemother Pharmacol. 1987;19(4):326-30. doi: 10.1007/BF00261482.
  • PMID: -
    Diaz CM, Fenix-Caballero SF, Palomo-Palomo C, Gandara-Ladronde Guevera MJ, Alegre-DelRey EJ, Blanco-Castano MA, Lopez-Vallejo JF, Diaz-Navarro J, Borrero-Rubio JM, Rios-Sanchez E: GM-006 Compliance with FDA recommendations about overdosing with carboplatin European Journal of Hospital Pharmacy: Science and Practice. 2014 Feb 24;21(Suppl 1):A116.
  • PMID: 6761010
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140-7. doi: 10.1007/BF00257742.

Contoh Produk & Brand

Produk: 88 • International brands: 1
Produk
  • Carboplatin
    Injection, powder, lyophilized, for solution • 50 mg/5mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection, powder, lyophilized, for solution • 150 mg/15mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection, powder, lyophilized, for solution • 450 mg/45mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection, powder, lyophilized, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection, powder, lyophilized, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection, powder, lyophilized, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Carboplatin
    Injection • 10 mg/1mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 88 produk.
International Brands
  • Paraplatin-AQ

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul